Association for Accessible Medicines
601 New Jersey Ave NW, Suite 850
Washington, DC 20001
E: [email protected]
As Senior Vice President, Global Biologics, Fouad leads USP’s Biologics program. His work focuses on the development and launch of solutions-based products and approaches for complex biologics such as monoclonal antibodies, proteins, vaccines, and cell and gene therapies. He leads USP’s collaboration with stakeholders in these areas and the exploration of new tools to enable manufacturing and quality of emerging therapeutic modalities.
Fouad joined USP in 2006 and has served in multiple scientific leadership roles developing quality tools for biologics and establishing relevant reference material programs. In addition to leading the modernization of existing standards, Fouad played a central role in the launch of USP’s biologics strategy in 2017, and since then has lead its implementation, focusing on technologies used to manufacture and test biological medicines.
In 2021, Fouad’s role expanded to include overall management and accountability for USP’s Biologics business unit. He has used innovative approaches for the launch of USP biological offerings and has implemented new models for engagement and collaboration with academia, biopharma industry, and global government agencies.
Recognized as a thought leader in the life sciences sector, Fouad is relied upon for his expertise, frequently representing USP at global pharmaceutical science events. Fouad has built a network of strong relationships with global stakeholders and continues to execute on collaborations with key partners that increase the visibility and growth of the USP biologics portfolio.